STOCK TITAN

Vanguard disaggregates holdings; reports 0 shares of Verastem (NASDAQ: VSTM)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Verastem Inc received an Amendment No. 2 to Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, certain Vanguard subsidiaries will report beneficial ownership separately. The filing states amount beneficially owned: 0 and percent of class: 0%. The amendment cites SEC Release No. 34-39538 (January 12, 1998) as the basis for disaggregated reporting and is signed by Vanguard's Head of Global Fund Administration.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings and reports zero direct ownership in Verastem.

The filing documents an internal realignment at The Vanguard Group on January 12, 2026, after which certain subsidiaries report holdings separately under SEC Release No. 34-39538. The Schedule 13G/A amendment shows amount beneficially owned: 0 and percent of class: 0%.

Practical implications depend on the separate subsidiary filings; subsequent amendments may show redistributed positions. Cash‑flow treatment and any subsidiary-level holdings are not detailed in the provided excerpt.






92337C203

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does the Schedule 13G/A amendment say about Vanguard's stake in Verastem (VSTM)?

The amendment states The Vanguard Group reports amount beneficially owned: 0 and percent of class: 0%. It explains holdings were disaggregated after an internal realignment on January 12, 2026 under SEC Release No. 34-39538.

Why did Vanguard file an amendment for Verastem (VSTM)?

Vanguard filed the amendment to reflect an internal realignment on January 12, 2026, causing certain subsidiaries or business divisions to report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Does the filing show any shares held indirectly by Vanguard in Verastem (VSTM)?

The filing lists the reporting entity's direct beneficial ownership as 0 shares (0%). It notes subsidiaries will report separately; subsidiary or managed‑account holdings are not detailed in the provided excerpt.

When was the Schedule 13G/A amendment signed and by whom for Verastem (VSTM)?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/27/2026, certifying the reported ownership and the realignment disclosure.

Does this amendment change who receives dividends or proceeds for Verastem (VSTM) shares?

The filing states The Vanguard Group and its managed accounts have the right to receive or direct dividends/proceeds where applicable, but no individual other person's interest exceeds 5% per the disclosure in the excerpt.
Verastem

NASDAQ:VSTM

View VSTM Stock Overview

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

447.08M
84.03M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM